Introduction: Paroxysmal supraventricular tachycardia (PSVT) is one of the most common forms of cardiac arrhythmia encountered in clinical practice. It is characterized by sudden episodes of abnormally fast heart rate that begin and end abruptly. These episodes can cause palpitations, dizziness, chest discomfort, shortness of breath, and anxiety, often sending patients to emergency departments repeatedly. …
Introduction: A Landmark Decision for Cardiovascular Health The landscape of cardiovascular medicine has been fundamentally reshaped by a recent, pivotal announcement: the Myqorzo FDA approval . This decision by the U.S. Food and Drug Administration (FDA) grants market access to Myqorzo (aficamten), a novel cardiac myosin inhibitor developed by Cytokinetics, for the treatment of adults …
Introduction Javadin Oral Solution, containing clonidine hydrochloride, is a prescription medication specifically approved for managing high blood pressure (hypertension) in adults. What makes it remarkable is that it is the first and only FDA-approved, immediate-release, ready-to-use liquid clonidine formulation available in the U.S. Traditional clonidine tablets are effective but may not be suitable for everyone—especially …
Introduction: Mavacamten FDA Approval The mavacamten FDA approval represents one of the most significant advancements in cardiovascular medicine in recent years. For decades, patients suffering from hypertrophic cardiomyopathy (HCM) had limited treatment options that primarily focused on symptom relief rather than addressing the root cause. Mavacamten, developed by MyoKardia (acquired by Bristol Myers Squibb), changes …
